EQ (Boldenone Undecylenate) 300mg/mL is an injectable anabolic research compound in MCT oil supplied in a 10mL vial. Manufactured for consistency, stability, and research applications.
Format10mL Vial
Concentration300mg/mL
CarrierMCT Oil
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Boldenone Undecylenate, widely known by its pharmaceutical brand name Equipoise (EQ), is a long acting synthetic anabolic compound derived from testosterone through a structural modification at the first carbon position. CSD’s 300mg/mL formulation delivers a higher concentration than the standard 250mg/mL Equipoise ampoule presentation in our range, supplied in a 10mL multi dose vial using MCT (medium chain triglyceride) oil as the carrier base; a deliberate pairing of high concentration with low viscosity carrier to maintain smooth administration characteristics at elevated compound loads per milliliter.
The undecylenate ester gives Equipoise a half life of approximately 14 days, requiring only weekly or twice weekly administration in documented research protocols to maintain stable blood concentration levels. At 300mg/mL this formulation reduces the injection volume required per dose compared to the 250mg/mL ampoule variant a meaningful practical consideration for researchers working with higher dose protocols where minimizing administration volume across weekly injections is a relevant variable. MCT oil’s ultra low viscosity further supports this by ensuring the higher concentration formulation draws and administers smoothly without the resistance that heavier oil carriers would present.
Boldenone’s structural relationship to testosterone produces a distinct research profile worth noting. The addition of a double bond at the first carbon position significantly reduces its rate of aromatization compared to testosterone estimated at approximately half the estrogenic conversion rate. This partial aromatization profile, combined with Equipoise’s notably long active window and well documented anabolic activity, makes it a frequently studied compound in comparative androgen research examining the relationship between structural modification, estrogenic conversion, and anabolic activity across testosterone derived compounds.
Every batch of CSD’s Equipoise 300mg/mL is third party lab tested for concentration accuracy and purity prior to release, with COA documentation available on request. Canada Steroid Depot stocks Boldenone Undecylenate across both 250mg/mL ampoule and this 300mg/mL MCT vial format, allowing researchers to select concentration and packaging format based on protocol requirements from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at room temperature away from direct light and heat. Do not freeze. Intended for research purposes only.
Commonly researched alongside a testosterone base compound and an aromatase inhibitor. Browse CSD’s full injectable range and PCT compounds for complete protocol sourcing.
Equipoise (Boldenone Undecylenate) is a testosterone derived anabolic compound originally developed as a veterinary injectable steroid. It has a moderate anabolic profile with lower androgenic activity than testosterone, aromatizes to estrogen at approximately 50% the rate of testosterone, and is particularly noted for its ability to significantly increase red blood cell production, elevating hematocrit and improving oxygen carrying capacity. Equipoise is researched for lean mass accretion, appetite stimulation, vascularity, endurance enhancement, and quality tissue gains with moderate water retention compared to testosterone at equivalent doses.
Standard Equipoise formulations are typically available at 200–250mg/mL. This 300mg/mL concentration delivers more active compound per mL of injection volume; a single 1mL injection delivers 300mg compared to 200–250mg from standard formulations. This higher concentration is particularly practical for research protocols targeting 600mg weekly doses; two 1mL injections per week deliver the full 600mg in a compact injection volume. The MCT oil carrier ensures the 300mg/mL concentration remains comfortably injectable through standard 23–25 gauge needles without pre warming.
Higher concentration injectable formulations typically require increased solvent levels to maintain all compound in stable solution, which can increase injection site discomfort and viscosity. MCT oil is one of the lightest and lowest viscosity carrier oils available, offsetting the increased viscosity that comes with higher compound concentrations. At 300mg/mL in MCT oil, this Equipoise formulation flows freely through standard injection needles at room temperature without pre warming; making it significantly more comfortable to administer than a 300mg/mL formulation in heavier carriers such as cottonseed or grape seed oil.
Due to its 14–16 day half-life, Equipoise is typically administered once or twice weekly; twice weekly administration splitting the weekly dose into two equal injections produces tighter plasma Boldenone stability. Common research doses range from 300–600mg per week. Hematocrit monitoring is an essential safety consideration in any Equipoise research protocol. Boldenone Undecylenate is one of the most potent erythropoiesis stimulating anabolic compounds, significantly elevating red blood cell production and hematocrit. Therapeutic phlebotomy, adequate hydration, and Telmisartan are the most commonly researched hematocrit management interventions.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming concentration accuracy at 300mg/mL and compound identity as Boldenone Undecylenate. A certificate of analysis is available.
